Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on January 18, 2019. The report details the determination of 2018 annual cash incentive compensation for the company's named executive officers by the Compensation Committee.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity figures. It specifically discloses the following executive compensation amounts awarded for 2018 performance:
- Andrew Rasdal: $520,000
- Kelly Huang: $199,800
- Bill Plovanic: $155,000
Material Changes and Performance Objectives
Executive bonuses were based on four equally weighted performance objectives: FDA approval, product quality metrics, EBITDASC (Earnings Before Interest, Taxes, Depreciation, Amortization, and Stock-Based Compensation), and revenue. The filing notes the following outcomes for 2018:
- Revenue Goal: Not achieved.
- FDA Approval Goal: "Upside" measure attained.
- EBITDASC Goal: "Upside" measure attained.
- Product Quality Goal: "Target" measure attained.
Management Commentary and Risks
Management commentary is limited to the rationale for the bonus awards, noting that despite missing the revenue target, the company achieved upside performance in regulatory and profitability metrics. The filing identifies the company as an "Emerging Growth Company" that has elected not to use the extended transition period for new accounting standards. No specific risks or contingencies beyond the standard performance metrics are detailed in this report.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Vyome Holdings, Inc.) and the filing registrant (Obalon Therapeutics, Inc.).
- Confirm the specific revenue shortfall that prevented the revenue goal from being met.
- Review the Form S-1 filed on January 4, 2019, for the original target bonus percentages and base salary figures.
- Assess the impact of the "upside" achievement on FDA approvals and EBITDASC on future operational milestones.